These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 27290654)

  • 21. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
    Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
    BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
    Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
    Awasthi A; Rolland DCM; Ayello J; van de Ven C; Basrur V; Conlon K; Fermin D; Barth MJ; Klein C; Elenitoba-Johnson KSJ; Lim MS; Cairo MS
    Oncotarget; 2017 Dec; 8(69):113895-113909. PubMed ID: 29371955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression.
    Medh RD; Saeed MF; Johnson BH; Thompson EB
    Cancer Res; 1998 Aug; 58(16):3684-93. PubMed ID: 9721879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interstitial pneumonia connected with rituximab therapy--case report].
    Wyrostkiewicz D; Skorupa W; Barańska I; Kuś J
    Pneumonol Alergol Pol; 2013; 81(5):453-9. PubMed ID: 23996885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of cyclic AMP/protein kinase A- and glucocorticoid-mediated apoptosis using S49 lymphoma cells as a model system.
    Keshwani MM; Kanter JR; Ma Y; Wilderman A; Darshi M; Insel PA; Taylor SS
    Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12681-6. PubMed ID: 26417071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab increases the cytotoxicities of vincristine and hydroxyurea through caspase-dependent and caspase-independent cell death, respectively.
    Tabal S; Elbanani A; Deyab M; Abulayha A
    Cancer Biother Radiopharm; 2015 Apr; 30(3):125-31. PubMed ID: 25714921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.
    Wang H; Wang Y; Rayburn ER; Hill DL; Rinehart JJ; Zhang R
    Int J Oncol; 2007 Apr; 30(4):947-53. PubMed ID: 17332934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
    Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexamethasone reduces mitomycin C-related inflammatory cytokine expression without inducing further cell death in corneal fibroblasts.
    Chang SW; Chou SF; Yu SY
    Wound Repair Regen; 2010; 18(1):59-69. PubMed ID: 20002897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.
    Daibata M; Bandobashi K; Kuroda M; Imai S; Miyoshi I; Taguchi H
    J Virol; 2005 May; 79(9):5875-9. PubMed ID: 15827204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
    Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
    Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
    Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
    J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
    Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
    Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.